Skip to main content
Premium Trial:

Request an Annual Quote

Hyseq Adds Four to Management Team

Premium

SUNNYVALE, Calif.--Gene-based therapeutics developer, Hyseq here announced four recent additions to its management team: Robert D'Elia, formerly an operations executive with Turner Construction and Eichleay Architects and Engineers, joined Hyseq as senior director of facilities operations; Stephanie Diaz, formerly of Martek Biosciences, joined as director of finance; Andrew Kumamoto came from the law firm McCutchen, Doyle, Brown and Enersen to be Hyseq's director of intellectual property; and Nandini Tandon joined the company as director of corporate development from Chiron where she was commercial development manager.

Hyseq applies the proprietary DNA array technology of its integrated HyX genomics platform to produce gene-based therapeutic product candidates. The company claims that its proprietary HyGenomics database of partial human gene sequences is the world's largest.

Filed under

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.